CM
AZN icon

Crestline Management’s AstraZeneca AZN Stock Holding History

Crestline Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,668
Closed -$2.45M – 65
2024
Q4 		$2.45M Sell
18,668
-11,967
-39% -$1.68M 0.08% 249
2024
Q3 		$4.77M Buy
+30,635
New +$4.95M 0.25% 109
2018
Q3 		– Sell
-77,145
Closed -$5.42M – 152
2018
Q2 		$5.42M Buy
77,145
+44,211
+134% +$3.18M 0.57% 15
2018
Q1 		$2.3M Buy
+32,934
New +$2.28M 0.29% 49

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Crestline Management's AZN Position: Q1 2025 in Review

Crestline Management sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 18,668 shares — an estimated $2.45M sold.

Crestline Management first reported a position in AZN in Q1 2018 and held it in 4 quarters. The position peaked at $5.42M in Q2 2018. 1,251 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

  • Crestline Management reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 18,668 AstraZeneca shares in Q1 2025, an estimated $2.45M.
  • Crestline Management first reported a position in AstraZeneca in Q1 2018 and held it in 4 quarters.
  • Crestline Management's AstraZeneca position peaked at $5.42M in Q2 2018.
  • 1,251 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.